- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03313297
Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (GC-SHealD)
A Double-blind, Randomized, Placebo-controlled Phase II Pilot Trial Investigating Efficacy, Safety and Feasibility of 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition by AZD4017 to Improve Skin Function and Wound Healing in Patients With Type 2 Diabetes
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Glucocorticoids are known to impair skin function and wound healing which are also compromised in patients with type 2 diabetes. The enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activates glucocorticoids in target tissues including skin. Pre-clinical data demonstrate that 11β-HSD1 inhibition improves skin function and wound healing but this has not been investigated in man.
Using the 11β-HSD1 inhibitor AZD4017, we will investigate if
- Oral AZD4017 inhibits 11β-HSD1 activity in skin
- AZD4017 is safe and well-tolerated in patient with T2DM
- Oral AZD4017 regulates skin function
- Systemic glucocorticoid levels and skin 11β-HSD1 activity, independently or in combination correlate with measures of skin function
Study feasibility will also be assessed; if successful, data from this pilot study will inform power calculations for a future trial to investigate the ability of 11β-HSD1 inhibition to promote foot ulcer healing in type 2 diabetes.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Leeds, Storbritannien, LS9 7TF
- Leeds Teaching Hospitals Trust
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Able and willing to consent
- Type 2 diabetes with HbA1c ≤11% (≤97 mmol/mol) at screening while taking standard therapy at a stable dose for ≥10 weeks
Exclusion Criteria:
- Women of child-bearing potential
- Active leg/foot ulceration
- Clinically relevant acute electrocardiogram anomalies
- Uncontrolled hypertension
- Endocrine disorder (other than type 2 diabetes ), including type 1 or secondary diabetes (except treated hypothyroidism)
- Gilbert's disease
- Alanine aminotransferase and/or aspartate aminotransferase and/or alkaline phosphatase >1.5x upper limit of normal (ULN)
- Bilirubin >1.5x ULN
- Estimated glomerular filtration rate <45 ml/min/m2
- Creatine kinase >2x ULN
- Drug abuse within the last year
- Any glucocorticoid treatment within 3 months of screening
- Anti-coagulant medication
- Probenecid therapy
- Medical/surgical procedure or trauma during drug administration or one week after drug cessation (excluding skin biopsies)
- Involvement in trial planning and/or conduct
- Participation in other clinical study within 1 month
- Deemed inappropriate to participate by the trial team
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: AZD4017
400mg oral AZD4017 twice daily for 35 days
|
AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity.
It is potent and highly selective in vitro and in vivo.
The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM.
AZD4017 is selective (> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
|
Placebo-jämförare: Placebo
A placebo tablet containing microcrystalline cellulose and sodium stearyl fumarate to match the active tablets in size, shape and colour.
|
Matchande placebo
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Skin 11β-HSD1 activity
Tidsram: Change between day 0 and day 28
|
Enzyme activity radioassay to evaluate AZD4107 efficacy in skin
|
Change between day 0 and day 28
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Urinary cortisol / cortisone metabolites
Tidsram: Change between day 0 and day 35
|
Urine samples for tetrahydrocortisol / tetrahydrocortisone metabolite ratios to evaluate systemic AZD4107 efficacy
|
Change between day 0 and day 35
|
AZD4017 in plasma
Tidsram: Change between day 0 and day 28
|
Quantification of AZD4017 concentration in plasma to evaluate systemic AZD4107 exposure
|
Change between day 0 and day 28
|
AZD4017 in skin
Tidsram: Change between day 0 and day 28
|
Quantification of AZD4017 concentration in plasma to evaluate skin AZD4107 exposure
|
Change between day 0 and day 28
|
Discontinuation due to Adverse Event
Tidsram: Day 42
|
Adverse Event-related participant withdrawals to evaluate safety
|
Day 42
|
Body mass index
Tidsram: Change between day 0 and day 35
|
Body mass index to evaluate safety
|
Change between day 0 and day 35
|
Waist-hip ratio
Tidsram: Change between day 0 and day 35
|
Waist-hip ratio to evaluate safety
|
Change between day 0 and day 35
|
Blood pressure (sphygmomanometer)
Tidsram: Change between day 0 and day 35
|
Blood pressure to evaluate safety
|
Change between day 0 and day 35
|
Sudomotor function
Tidsram: Change between day 0 and day 35
|
Conducted with a Sudoscan device to measure c-fiber innervation in hands and feet for skin function
|
Change between day 0 and day 35
|
Skin hydration
Tidsram: Change between day 0 and day 35
|
Conducted with a Corneometer device to measure skin water content for skin function
|
Change between day 0 and day 35
|
Epidermal barrier function
Tidsram: Change between day 0 and day 35
|
Conducted with a Tewameter device to measure skin trans-epidermal water loss for skin function
|
Change between day 0 and day 35
|
Epidermal barrier integrity
Tidsram: Change between day 0 and day 28
|
Conducted by tape tripping to a pre-determined trans-epidermal water loss rate for skin function
|
Change between day 0 and day 28
|
Skin thickness
Tidsram: Change between day 0 and day 35
|
Conducted by Optical Coherence Tomography imaging for skin function
|
Change between day 0 and day 35
|
Wound healing
Tidsram: Change between day 0 and day 2
|
Conducted by Optical Coherence Tomography imaging for skin function
|
Change between day 0 and day 2
|
Wound healing
Tidsram: Change between day 0 and day 7
|
Conducted by Optical Coherence Tomography imaging for skin function
|
Change between day 0 and day 7
|
Wound healing
Tidsram: Change between day 28 and day 30
|
Conducted by Optical Coherence Tomography imaging for skin function
|
Change between day 28 and day 30
|
Wound healing
Tidsram: Change between day 28 and day 35
|
Conducted by Optical Coherence Tomography imaging for skin function
|
Change between day 28 and day 35
|
Skin RNA-seq gene expression profiling
Tidsram: Change between day 0 and day 28
|
For skin function
|
Change between day 0 and day 28
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ED17/93260
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes mellitus, typ 2
-
Mathias Ried-LarsenAvslutadDiabetes mellitus, typ 2 | Typ 2-diabetes mellitus | Diabetes typ 2 | Typ 2 diabetes mellitusDanmark
-
SanofiAvslutadTyp 1-diabetes mellitus-typ 2-diabetes mellitusUngern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
-
Hanmi Pharmaceutical Company LimitedOkändTyp 2 diabetes mellitus | Typ 1 diabetes mellitusFörenta staterna
-
Tanta UniversityRekrytering
-
Boryung Pharmaceutical Co., LtdAvslutad
-
Georgia Institute of TechnologyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) och andra samarbetspartnersAvslutadTyp 2 diabetes mellitusFörenta staterna
-
TheracosAvslutadTyp 2 diabetes mellitusFörenta staterna
-
Chong Kun Dang PharmaceuticalOkänd
-
Chong Kun Dang PharmaceuticalOkändTyp 2 diabetes mellitusKorea, Republiken av
Kliniska prövningar på Placebo
-
SamA Pharmaceutical Co., LtdOkändAkut bronkit | Akut övre luftvägsinfektionKorea, Republiken av
-
National Institute on Drug Abuse (NIDA)AvslutadAnvändning av cannabisFörenta staterna
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAvslutadManliga försökspersoner med typ II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAvslutadFarmakokinetik | SäkerhetsfrågorStorbritannien
-
Texas A&M UniversityNutraboltAvslutadGlucose and Insulin Response
-
Longeveron Inc.AvslutadHypoplastiskt vänsterhjärtsyndromFörenta staterna
-
Regado Biosciences, Inc.AvslutadFrisk volontärFörenta staterna
-
ItalfarmacoAvslutadBeckers muskeldystrofiNederländerna, Italien
-
Universidade Estadual de LondrinaConselho Nacional de Desenvolvimento Científico e Tecnológico; Coordination...AvslutadVassleproteintillskott associerat med motståndsträning på hälsoindikatorer hos tränade äldre kvinnorFriska | Kroppssammansättning